Covered recipient · General Payments record
JONATHAN A ROSENBERG
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$151,950.45
325 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,580.00 | 32 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $26,300.00 | 7 |
| Travel and Lodging | $20,955.13 | 84 |
| Consulting Fee | $6,530.00 | 2 |
| Food and Beverage | $5,502.94 | 198 |
| Honoraria | $2,080.00 | 1 |
| Education | $2.38 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Allergan Inc. | $111,161.93 | 153 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35,012.58 | 46 |
| Horizon Therapeutics plc | $2,409.46 | 2 |
| Boston Scientific Corporation | $1,692.44 | 9 |
| Janssen Biotech, Inc. | $257.89 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. | $181.85 | 28 |
| AbbVie, Inc. | $165.55 | 8 |
| Gilead Sciences, Inc. | $162.33 | 12 |
| PFIZER INC. | $142.13 | 9 |
| Ironwood Pharmaceuticals, Inc | $136.69 | 5 |
| QOL Medical, LLC | $117.93 | 10 |
| Merck Sharp & Dohme Corporation | $95.14 | 6 |
| UCB, Inc. | $85.44 | 5 |
| Daiichi Sankyo Inc. | $77.99 | 4 |
| Shionogi Inc | $56.78 | 3 |
| ABIOMED | $44.25 | 1 |
| Braintree Laboratories, Inc. | $41.51 | 2 |
| Intercept Pharmaceuticals, Inc. | $39.63 | 3 |
| Dova Pharmaceuticals | $39.61 | 2 |
| Ferring Pharmaceuticals Inc. | $17.86 | 1 |
| Concordia Pharmaceuticals Inc. | $11.46 | 1 |
Page 6 of 7; records 251–300 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JONATHAN A ROSENBERG
NPI 1811150725 · CMS profile ID 37047
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
GURNEE, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 7; records 251–300 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JONATHAN A ROSENBERG, NPI 1811150725, CMS profile ID 37047. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JONATHAN A ROSENBERG, NPI 1811150725, CMS profile ID 37047. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JONATHAN A ROSENBERG, NPI 1811150725, CMS profile ID 37047, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
325 matching records · $151,950.45 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 325.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Allergan Inc. | $31.33 | 03/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043872 | CMS |
| Ironwood Pharmaceuticals, Inc | $92.83 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709208007 | CMS |
| QOL Medical, LLC | $12.49 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637741929 | CMS |
| UCB, Inc. | $20.06 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688269393 | CMS |
| Allergan Inc. | $200.00 | 03/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043827 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.34 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911709 | CMS |
| AbbVie, Inc. | $19.60 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647901297 | CMS |
| Horizon Therapeutics plc | $329.46 | 03/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691483513 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $11.34 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682104855 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $0.36 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682046457 | CMS |
| Ferring Pharmaceuticals Inc. | $17.86 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655214335 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2.38 | 02/28/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911707 | CMS |
| UCB, Inc. | $13.49 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688260471 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.97 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911701 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3.44 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911703 | CMS |
| Allergan Inc. | $19.40 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043823 | CMS |
| Allergan Inc. | $12.35 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043765 | CMS |
| Allergan Inc. | $55.36 | 02/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043771 | CMS |
| Allergan Inc. | $73.00 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043775 | CMS |
| Allergan Inc. | $4,530.00 | 02/23/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043781 | CMS |
| Allergan Inc. | $12.36 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043785 | CMS |
| Allergan Inc. | $52.66 | 02/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043791 | CMS |
| Allergan Inc. | $68.85 | 02/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043793 | CMS |
| Allergan Inc. | $123.00 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043797 | CMS |
| Allergan Inc. | $123.00 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043803 | CMS |
| Allergan Inc. | $307.77 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043810 | CMS |
| Allergan Inc. | $5.00 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043815 | CMS |
| Allergan Inc. | $556.60 | 02/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043819 | CMS |
| Allergan Inc. | $3.88 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043756 | CMS |
| Allergan Inc. | $119.99 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043761 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,300.00 | 02/22/2019 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911697 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,239.10 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911689 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $70.53 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684911693 | CMS |
| Dova Pharmaceuticals | $19.93 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705232947 | CMS |
| QOL Medical, LLC | $12.63 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637741931 | CMS |
| Concordia Pharmaceuticals Inc. | $11.46 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 639781795 | CMS |
| Allergan Inc. | $12.59 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043751 | CMS |
| Janssen Biotech, Inc. | $5.44 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658678655 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2.09 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681762243 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2.72 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681763567 | CMS |
| Allergan Inc. | $19.50 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043725 | CMS |
| Allergan Inc. | $3,300.00 | 02/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043727 | CMS |
| Allergan Inc. | $16.15 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043735 | CMS |
| Allergan Inc. | $287.59 | 02/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043741 | CMS |
| Allergan Inc. | $2,200.00 | 02/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043743 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $10.61 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682077977 | CMS |
| Allergan Inc. | $8.77 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043676 | CMS |
| Allergan Inc. | $17.41 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043681 | CMS |
| Allergan Inc. | $61.07 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043687 | CMS |
| Allergan Inc. | $31.14 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671043691 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $96.39 | 1 |
| PY2025 | Principal investigator | $708,726.43 | 147 |
| PY2024 | Principal investigator | $664,829.42 | 149 |
| PY2023 | Principal investigator | $465,280.81 | 125 |
| PY2022 | Principal investigator | $137,067.90 | 52 |
| PY2021 | Principal investigator | $21,800.00 | 2 |
| PY2020 | Principal investigator | $20,268.64 | 31 |
| PY2019 | Recipient | $1,932.14 | 6 |
| PY2019 | Principal investigator | $87,072.39 | 26 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
148 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $3,850.00 | 12/31/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202535287 |
| Principal investigator 1 | ABBVIE INC. | $14,149.80 | 12/30/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202532206 |
| Principal investigator 1 | ABBVIE INC. | $91,714.00 | 12/30/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202532208 |
| Principal investigator 1 | Genentech, Inc. | $14,308.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 12/17/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.43 | 12/17/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.43 | 12/17/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.43 | 12/17/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.43 | 12/17/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786315 |
| Principal investigator 1 | Genentech, Inc. | $4,725.00 | 12/11/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663491 |
| Principal investigator 1 | Eli Lilly and Company | $324.14 | 12/08/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187893116 |
| Principal investigator 1 | ABBVIE INC. | $3,081.40 | 12/04/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202528222 |
| Principal investigator 1 | Phathom Pharmaceuticals, Inc. | $3,000.00 | 12/01/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSUL | EoE-201 | No dispute reported | 06/30/2026 | 1224868881 |
| Principal investigator 1 | Phathom Pharmaceuticals, Inc. | $12,000.00 | 12/01/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSUL | EoE-201 | No dispute reported | 06/30/2026 | 1224869010 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $29,940.00 | 11/21/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Southlake | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1235993305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $154.00 | 11/13/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,195.20 | 11/13/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,195.20 | 11/13/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,410.00 | 11/13/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786293 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786305 |
| Principal investigator 1 | ABBVIE INC. | $2,696.40 | 10/09/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202514081 |
| Principal investigator 1 | PFIZER INC. | $680.00 | 10/09/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants PLLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228748288 |
| Principal investigator 1 | Genentech, Inc. | $392.00 | 09/24/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663336 |
| Principal investigator 1 | Genentech, Inc. | $867.00 | 09/24/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663346 |
| Principal investigator 1 | Genentech, Inc. | $3,390.00 | 09/18/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663297 |
| Principal investigator 1 | ABBVIE INC. | $4,554.20 | 09/04/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202508782 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $1,908.20 | 09/04/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 08/26/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786283 |
| Principal investigator 1 | Genentech, Inc. | $1,695.00 | 08/21/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663289 |
| Recipient | Eli Lilly and Company | $96.39 | 08/19/2025 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187871051 |
| Principal investigator 1 | GENZYME CORPORATION | $2,085.70 | 08/18/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120714 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $9,341.00 | 08/14/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060858 |
| Principal investigator 1 | ABBVIE INC. | $8,334.20 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202502268 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223283819 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223283821 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223283835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223283839 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223283841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,145.40 | 07/30/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,588.20 | 07/30/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,441.20 | 07/30/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 07/28/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786281 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $628.29 | 07/25/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060806 |
| Principal investigator 1 | Genentech, Inc. | $160.00 | 07/22/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663293 |
| Principal investigator 1 | GENZYME CORPORATION | $1,050.00 | 07/21/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120691 |
| Principal investigator 1 | PFIZER INC. | $6,494.00 | 07/14/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants PLLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228724690 |
| Principal investigator 1 | PFIZER INC. | $3,366.00 | 07/11/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants PLLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228743657 |
| Principal investigator 1 | ABBVIE INC. | $10,007.20 | 07/02/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202494753 |
| Principal investigator 1 | GENZYME CORPORATION | $194.05 | 07/02/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120677 |
| Principal investigator 1 | GENZYME CORPORATION | $45,381.00 | 07/02/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 06/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 06/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 06/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 06/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 06/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 06/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786267 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $37,849.00 | 06/24/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060680 |
| Principal investigator 1 | ABBVIE INC. | $5,392.80 | 06/12/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202491371 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 06/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223280820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786279 |
| Principal investigator 1 | Genentech, Inc. | $2,922.00 | 05/27/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663234 |
| Principal investigator 1 | ABBVIE INC. | $21,500.00 | 05/15/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202485153 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $533.40 | 05/15/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.89 | 05/08/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 05/08/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/08/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/08/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786243 |
| Principal investigator 1 | Genentech, Inc. | $3,447.00 | 05/08/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663134 |
| Principal investigator 1 | ABBVIE INC. | $6,463.80 | 05/07/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202483769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786245 |
| Principal investigator 1 | Genentech, Inc. | $976.00 | 04/30/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.65 | 04/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.20 | 04/24/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 04/23/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 04/23/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 04/23/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 04/23/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 04/23/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786255 |
| Principal investigator 1 | PFIZER INC. | $2,542.00 | 04/23/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228790266 |
| Principal investigator 1 | PFIZER INC. | $1,906.00 | 04/23/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228790512 |
| Principal investigator 1 | PFIZER INC. | $294.00 | 04/23/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228791509 |
| Principal investigator 1 | PFIZER INC. | $1,358.00 | 04/23/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228791512 |
| Principal investigator 1 | PFIZER INC. | $810.00 | 04/23/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228791763 |
| Principal investigator 1 | PFIZER INC. | $74.00 | 04/23/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228792159 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 04/09/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223277648 |
| Principal investigator 1 | Genentech, Inc. | $3,188.00 | 04/08/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $225.00 | 04/07/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $161.00 | 04/07/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786231 |
| Principal investigator 1 | ABBVIE INC. | $2,871.40 | 04/03/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202471173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786233 |
| Principal investigator 1 | Genentech, Inc. | $18,040.00 | 04/01/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211663148 |
| Principal investigator 1 | Genentech, Inc. | $3,400.00 | 04/01/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211663201 |
| Principal investigator 1 | Genentech, Inc. | $976.00 | 03/28/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663048 |
| Principal investigator 1 | Genentech, Inc. | $7,695.00 | 03/25/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | No dispute reported | 06/30/2026 | 1211663074 |
| Principal investigator 1 | Genentech, Inc. | $2,928.00 | 03/21/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663054 |
| Principal investigator 1 | PFIZER INC. | $680.00 | 03/21/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants PLLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228786776 |
| Principal investigator 1 | PFIZER INC. | $6,132.50 | 03/19/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228775548 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $74.20 | 03/13/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060264 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $1,257.20 | 03/13/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | No dispute reported | 06/30/2026 | 1242060269 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,554.95 | 03/13/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants, PLLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244044704 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,100.00 | 03/13/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants, PLLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244044706 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 03/12/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223276285 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 03/12/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223276287 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $668.25 | 03/12/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223276289 |
| Principal investigator 1 | ABBVIE INC. | $5,952.80 | 03/07/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202459499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,078.00 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,540.00 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,500.00 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,617.86 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.34 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.21 | 03/06/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 03/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786235 |
| Principal investigator 1 | Genentech, Inc. | $976.00 | 02/28/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLCD B A GI ALLIANCE | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.21 | 02/26/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $128.26 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,022.00 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786213 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.55 | 02/25/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786223 |
| Principal investigator 1 | GENZYME CORPORATION | $525.00 | 02/24/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120626 |
| Principal investigator 1 | GENZYME CORPORATION | $24,024.00 | 02/24/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120638 |
| Principal investigator 1 | GENZYME CORPORATION | $9,704.80 | 02/24/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120642 |
| Principal investigator 1 | GENZYME CORPORATION | $1,467.35 | 02/18/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120653 |
| Principal investigator 1 | ABBVIE INC. | $14,460.60 | 02/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202449442 |
| Principal investigator 1 | GENZYME CORPORATION | $55,669.00 | 02/04/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Pllc Gi Alliance | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) | No dispute reported | 06/30/2026 | 1226120646 |
| Principal investigator 1 | PFIZER INC. | $1,309.00 | 02/03/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants PLLC | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228775556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 02/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786277 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $14.75 | 01/27/2025 | Non-covered Recipient Entity GI Alliance Of Illinois | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235997105 |
| Principal investigator 1 | Genentech, Inc. | $6,832.00 | 01/24/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLCD B A GI ALLIANCE | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211663518 |
| Principal investigator 1 | Celgene Corporation | $35,614.25 | 01/17/2025 | Non-covered Recipient Entity GI Alliance Department Of Clinical Research And Education | A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cendakimab | No dispute reported | 06/30/2026 | 1222306889 |
| Principal investigator 1 | Celgene Corporation | $22,656.40 | 01/13/2025 | Non-covered Recipient Entity GI Alliance Department Of Clinical Research And Education | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222307009 |
| Principal investigator 1 | Bausch Health US, LLC | $448.00 | 01/10/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants, PLLC | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224846354 |
| Principal investigator 1 | Bausch Health US, LLC | $357.00 | 01/10/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants, PLLC | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224846380 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,950.00 | 01/10/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Southlake | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235993303 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,277.35 | 01/07/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants, PLLC | A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) | No dispute reported | 06/30/2026 | 1244044702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 01/01/2025 | Non-covered Recipient Entity GI Alliance Of Illinois-Gurnee | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220786189 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 1 |
| PY2024 | Value of interest | $19,997.26 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $19,997.26 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $1,256.05 | 1 |
| PY2021 | Amount invested | $993.05 | 1 |
| PY2021 | Value of interest | $1,241.66 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
4 records · PY2021–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | GastroGPO, LLC | $0.00 | $19,997.26 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124820162 |
| PY2023 | GastroGPO, LLC | $0.00 | $19,997.26 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1050730571 |
| PY2022 | GastroGPO, LLC | $0.00 | $1,256.05 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 955001069 |
| PY2021 | GastroGPO, LLC | $993.05 | $1,241.66 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 854914347 |